argenx: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Oct. 22, 2026, argenx (NASDAQ:ARGX) reported $1.7 billion in quarterly product sales and outlined expansion plans across its immunology pipeline. Expanding sales of VYVGART, a treatment for autoimmune neuromuscular conditions, generate cash that fuels new late-stage drug development. Three takeaways stand out for long-term investors.

1. VYVGART Sales Grew 54% Year Over Year on Broader Patient Adoption

Product revenue rose because more patients began using VYVGART to manage generalized myasthenia gravis, an autoimmune neuromuscular disease, and chronic inflammatory demyelinating polyneuropathy, a neurological disorder causing nerve damage.

Product net sales were $1.7 billion, representing growth of 54% year-over-year and 13% quarter-over-quarter.
-- Karl Gubitz, Chief Financial Officer

2. Pipeline Expansion Creates New Growth Pillars Beyond Core Treatments

The business is diversifying its clinical trials into empasiprubart for multifocal motor neuropathy, a nerve disease affecting muscle movement, and FB102 for celiac disease to reduce dependency on a single drug.

Beyond VYVGART, we're building what comes next for argenx. We're advancing empasiprubart toward its first phase 3 readout in MMN. And we had positive phase 2 results for FB102 in celiac disease, just months after the Forte acquisition, giving us another phase 3-ready program.
-- Karen Massey, Chief Executive Officer

3. Operating Profit Reached $486 Million as Operating Leverage Improved

Operating profit reached $486 million as top-line gains covered higher research and development expenses, allowing management to fund 10 clinical-stage molecules without eroding profitability.

Revenue growth continues to outpace expense growth, demonstrating the operating leverage in our business while supporting investment for future growth.
-- Karl Gubitz, Chief Financial Officer

Looking Ahead

Commercial expansion accelerates as argenx prepares for up to five potential product launches in 2027 while scaling infrastructure for autoimmune myositis, an inflammatory muscle disease. Broad insurance coverage and clinical execution support early adoption.

As we look ahead, 2027 will be an important year in the evolution of argenx with 5 potential launches across our portfolio. Together, they would mark significant progress toward Vision 2030.
-- Karen Massey, Chief Executive Officer

The company maintains disciplined cost allocation while advancing 10 clinical-stage molecules to extend long-term operating leverage.

Our capital allocation priorities remain clear: strengthen the VYVGART franchise, advance a diversified pipeline for future growth and maintain the financial flexibility to execute our strategy as we deliver on Vision 2030.
-- Karl Gubitz, Chief Financial Officer

The Motley Fool has positions in and recommends Argenx Se. The Motley Fool has a disclosure policy.